Invest in CINV
A fully integrated seed-to-sale business
Financial Highlights
Why CINV?
Scalable Growth Model
CINV’s infrastructure is designed for expansion, leveraging a strong supply chain and cultivation oversight to meet the growing demand for plant-based therapeutics in the UK and Europe.
✔ Licensed Facility: Ownership of a fully licensed cultivation and cloning facility in South Africa, providing access to high-quality genetics and stable production.
✔ Global Cultivation Network: Oversees certified indoor cultivators and strategic out-grow partnerships for quality assurance and to increase supply capacity.
✔ Expansion Ready: Designed for scalability, ensuring long-term supply chain resilience and adaptability in a rapidly evolving regulatory landscape.
Get Started
Join us in shaping the future of plant therapeutics in the UK and Europe
Medical flower may be prescribed for a range of conditions that haven’t responded to traditional treatments. These include chronic pain, anxiety, PTSD, multiple sclerosis, epilepsy, and cancer-related symptoms.
Join us as we fight to expand access, improve education and set a benchmark for cultivation, manufacturing, operational oversight and patient experience.
CINV is an asset-backed, vertically integrated business facilitating the production, import, and distribution of high-quality, regulated medical flower across the UK and Europe.
We bridge genetics, cultivation oversight, and patient access to meet the growing demand for plant-based therapeutic solutions, soon to be trading on the OTCQB.
A Pioneering Medical Flower Company Expanding in the UK & Europe
Investment Highlights
Market Potential of $13.8bn
Full Vertical Integration, from Seed to Sale
Expanding UK Retail Proposition
Scalable Growth Model
Market Potential
The European market for plant therapeutics is expected to reach
driven by increased patient access and regulatory advancements.
$13.8 billion
by 2028*
*A CAGR of 19% over forecast period.
Source: Research and Markets
By controlling every stage of the process, CINV ensures consistency, safety, and compliance from genetics to patient access.
✔ Genetics & Cultivation Oversight: Facilitates the production of quality cultivars, focusing on stability, potency, and therapeutic value.
✔ Import/Export Management: Ensures seamless international distribution while maintaining strict regulatory compliance in all markets.
✔ Manufacturing & Distribution: Works with licensed EU-GMP-certified partners to process and distribute formulations through compliant medical channels.
Expanding UK Retail Proposition
CINV is positioned to provide patients with high-quality, regulated plant-based therapeutics through multiple access points in the UK, with the first import due to arrive in Q1 2025.
✔ Licensed Retail & Specialist Clinics: Products are available through trusted, compliant distribution channels.
✔ Online Pharmaceutical Dispensary: A streamlined platform for prescription management and home delivery.
✔ Patient-Centric Approach: Committed to improving accessibility, affordability, and education around plant-based medicine.
Full Vertical Integration, from Seed to Sale
INVESTMENT OFFERING
Private Placement Pre-Listing
PwC VALUATION
$97.3M - $103.7M
$25,000
MINIMUM INVESTMENT
CINV
3773 Howard Hughes Parkway Suite, 500S, Las Vegas, 89169
London, 3rd Floor, 86-90 Paul Street, London EC2A 4NE